診斷專用抗體市場－全球產業規模、佔有率、趨勢、機會及預測（按抗體、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球診斷專用抗體市場預計將從 2025 年的 281.2 億美元成長到 2031 年的 390.2 億美元，複合年成長率為 5.61%。

這些特製的單株和多株抗體專為體外診斷檢測而設計，用於識別與特定疾病狀態相關的生物標記。推動這一成長的關鍵因素包括：全球慢性病和感染疾病發病率的上升，這促使人們需要精準的早期檢測；以及依賴準確患者分層的個人化醫療的日益普及。此外，全球人口老化也持續推高了對高頻診斷檢測和免疫組織化學檢測服務的強勁需求。

儘管有這些積極跡象，但該行業仍面臨許多挑戰，包括由於新型診斷劑的檢驗和商業化法規結構嚴格，導致研發週期過長。這些合規要求可能會阻礙創新解決方案的快速應用，即便臨床需求迫切。美國癌症協會的數據凸顯了這項需求，該協會預測，到2024年，美國將新增超過200萬例癌症病例。如此沉重的疾病負擔凸顯了先進診斷工具的必要性，而監管的複雜性仍然是市場擴張的主要障礙。

市場促進因素

慢性病和感染疾病的日益普及是推動全球診斷專用抗體市場成長的主要因素。在疾病負擔不斷加重的情況下，醫療基礎設施越來越依賴基於抗體的檢測方法來準確識別和監測病原體。世界衛生組織（世衛組織）於2024年10月發布的《2024年全球結核病報告》顯示，2023年全球新增結核病病例約820萬例，這將是自全球開始追蹤結核病以來的最高數字。此外，非傳染性疾病的廣泛流行也使得持續的生物標記監測變得特別必要。國際糖尿病聯盟的報告指出，到2024年，全球約有5.89億成年人患有糖尿病，凸顯了需要持續監測的慢性疾病規模之大。

個人化醫療和伴隨診斷的進步也在推動市場擴張方面發揮關鍵作用。現代治療方法，尤其是在腫瘤治療領域，高度依賴抗體介導的檢測來識別治療前的特定生物標記物，凸顯了特異性抗體在患者分層中的不可或缺性。因此，主要市場參與企業正經歷持續成長。例如，根據羅氏公司於2025年1月發布的2024年年度報告，該公司診斷部門的銷售額預計將成長4%，達到143億瑞士法郎，這主要得益於對免疫診斷產品和伴隨診斷的強勁需求。這項財務上的成功證實了高特異性抗體在推動精準醫療方面發揮的關鍵作用。

市場挑戰

針對新型診斷劑的檢驗和商業化，嚴格的監管框架對全球診斷專用抗體市場的成長構成了重大障礙。世界各地的監管機構正在實施日益嚴格的臨床證據標準，以確認體外診斷 (IVD) 測試中所用抗體的敏感度和特異性。這些合規要求需要進行全面的數據收集和漫長的臨床試驗，從而顯著延長了研發週期並增加了資本成本。因此，製造商往往被迫將大量資源從研發轉移到合規性要求上，造成瓶頸，延緩了用於檢測複雜疾病狀態的新型生物標記的推出。

這些營運壓力阻礙了產品在法規環境複雜的地區上市，直接限制了市場擴張。核准時間的不確定性構成了進入壁壘，影響著成熟和新興的生物技術公司，迫使它們精簡產品組合或放棄小眾診斷應用。 MedTech Europe 2024年的行業調查數據顯示，由於監管的複雜性，選擇歐盟作為主要產品上市地區的領先診斷製造商比例下降了40%，凸顯了市場活動的下滑。此類策略調整和延誤限制了關鍵診斷工具的獲取，並最終限制了產業的獲利潛力。

市場趨勢

將人工智慧 (AI) 應用於抗體發現和設計，透過縮短篩檢時間和提高結合親和性，正在徹底改變特異性診斷抗體的開發。生成式 AI 模型現在可以預測蛋白質結構並設計具有高特異性的新型抗體序列，從而為傳統的、勞動密集的動物免疫方法提供了一種替代方案。這項技術進步使得針對以往無法治療的標靶快速生成抗體成為可能，顯著加速了新型診斷檢測的商業化。為了強調對 AI 驅動生物學的這項投資，2024 年 4 月 Business Wire 發布的新聞稿《Xaira Therapeutics 成立，旨在透過加速和利用 AI 在藥物發現和開發中的應用，提供變革性藥物》宣布，Xaira Therapeutics 已籌集超過 10 億美元的承諾資本，旨在透過 AI 的抗體端到端應用，徹底的抗體發現過程和藥物應用。

同時，即時檢測（POC​​）抗體診斷技術的顯著發展正推動市場去中心化，將檢測流程從中心檢查室轉移到基層醫療機構和藥房。這一趨勢的驅動力源於對快速臨床決策的需求，利用高親和性抗體和小型微流體進行快速橫向流動化驗，可在數分鐘內識別病原體和慢性病生物標記。因此，領先的診斷公司正積極收購專業技術，以增強其分散式檢查能力。羅氏公司在2024年7月發布的題為「羅氏完成對LumiraDx POC技術的收購，擴大基層醫療的診斷檢測覆蓋範圍」的新聞稿中宣布，已完成對LumiraDx POC技術的收購，交易金額為2.95億美元，旨在加強其在全球去中心化診斷領域的業務。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球診斷抗體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依抗體類型（單株抗體、多株抗體、重組多株抗體）
  • 依應用領域（登革熱診斷、愛滋病診斷、肝炎診斷、感染疾病診斷、腫瘤診斷、結核病診斷）
  • 依最終用戶（診斷檢查室、醫院等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美診斷專用抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲診斷特殊抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區診斷專用抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲診斷專用抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲診斷特殊抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球診斷專用抗體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Diagnostic Specialty Antibodies Market is anticipated to expand from USD 28.12 Billion in 2025 to USD 39.02 Billion by 2031, reflecting a CAGR of 5.61%. These specialized monoclonal and polyclonal antibodies are engineered specifically for in vitro diagnostic assays to identify biomarkers linked to specific pathologies. Key factors fueling this growth include the rising global incidence of chronic and infectious diseases, which drives the need for precise early detection, as well as the increasing implementation of personalized medicine that relies on accurate patient stratification. Additionally, the aging global population continues to generate strong demand for high-volume diagnostic testing and immunohistochemistry services.

Despite these positive indicators, the industry encounters substantial obstacles due to rigorous regulatory frameworks regarding the validation and commercialization of new diagnostic reagents, which often prolong development schedules. These compliance requirements can hinder the swift introduction of innovative solutions, even when clinical needs are urgent. This demand is highlighted by data from the American Cancer Society, which projects that over two million new cancer cases will be diagnosed in the United States in 2024. This significant disease burden emphasizes the essential need for sophisticated diagnostic tools, even as regulatory complexities persist as a major hurdle to market expansion.

Market Driver

The escalating prevalence of chronic and infectious diseases serves as a major engine for growth in the global diagnostic specialty antibodies market. As the burden of disease intensifies, healthcare infrastructure is increasingly dependent on antibody-based assays for the precise identification and monitoring of pathogens. According to the 'Global Tuberculosis Report 2024' released by the World Health Organization in October 2024, approximately 8.2 million individuals were newly diagnosed with tuberculosis in 2023, marking the highest figure since global tracking commenced. Moreover, the widespread nature of non-communicable diseases requires continuous biomarker monitoring; the International Diabetes Federation reported that approximately 589 million adults globally were living with diabetes in 2024, highlighting the immense scale of chronic conditions necessitating persistent surveillance.

The advancement of personalized medicine and companion diagnostics also plays a pivotal role in driving market expansion. Contemporary therapeutic approaches, especially within oncology, rely heavily on antibody-mediated testing to pinpoint specific biomarkers prior to administering treatment, ensuring that specialty antibodies remain vital for patient stratification. Consequently, major industry participants are experiencing continued growth. For instance, Roche's 'Annual Report 2024', published in January 2025, revealed that their Diagnostics Division sales rose by 4% to CHF 14.3 billion, a performance attributed largely to robust demand for immunodiagnostic products and companion diagnostics. This financial success confirms the indispensable role of high-specificity antibodies in facilitating precision medicine.

Market Challenge

Strict regulatory frameworks controlling the validation and commercialization of new diagnostic reagents present a major obstacle to the growth of the Global Diagnostic Specialty Antibodies Market. Authorities worldwide are implementing increasingly stringent standards for clinical evidence to confirm the sensitivity and specificity of antibodies utilized in in vitro diagnostic (IVD) assays. These compliance mandates require comprehensive data gathering and extended clinical trials, which significantly prolong development timelines and increase capital costs. As a result, manufacturers are frequently forced to redirect vital resources from research and development toward compliance efforts, creating a bottleneck that slows the introduction of novel biomarkers necessary for detecting complex pathologies.

This operational pressure directly inhibits market expansion by deterring product launches in regions defined by complicated regulatory environments. The uncertainty surrounding approval timelines establishes a barrier to entry that impacts both established corporations and emerging biotechnology companies, compelling them to streamline portfolios and discard niche diagnostic applications. Highlighting this reduction in market activity, industry survey data from MedTech Europe in 2024 indicated that the choice of the European Union as the primary region for initial product launches fell by 40 percent among major diagnostic manufacturers due to these regulatory intricacies. Such strategic pivots and delays restrict the accessibility of critical diagnostic tools, ultimately limiting the sector's revenue potential.

Market Trends

The incorporation of Artificial Intelligence into antibody discovery and design is fundamentally transforming the development of diagnostic specialty antibodies by shortening screening durations and enhancing binding affinity. Generative AI models now have the capacity to predict protein structures and engineer novel antibody sequences with high specificity, thereby circumventing traditional, labor-intensive animal immunization methods. This technological evolution facilitates the rapid generation of antibodies against targets previously considered undruggable, significantly speeding up the commercialization of new diagnostic assays. Emphasizing this investment in AI-driven biology, a press release from Business Wire in April 2024 titled 'Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development' announced that Xaira Therapeutics debuted with over $1 billion in committed capital to revolutionize antibody and drug discovery through end-to-end AI applications.

Concurrently, a notable transition toward Point-of-Care (POC) antibody-based diagnostic testing is decentralizing the market, shifting testing procedures from centralized laboratories to primary care environments and pharmacies. This trend is fueled by the necessity for immediate clinical decision-making, utilizing rapid lateral flow assays and compact microfluidic devices that employ high-affinity antibodies to identify pathogens or chronic biomarkers within minutes. Consequently, leading diagnostic firms are aggressively acquiring specialized technologies to bolster their decentralized testing capabilities. Confirming this strategic consolidation, Roche announced in July 2024, in 'Roche closes acquisition of LumiraDx's Point of Care technology to expand access to diagnostic testing in primary care', that it had finalized the acquisition of LumiraDx's point-of-care technology for USD 295 million to strengthen its global offerings in decentralized diagnostics.

Key Market Players

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

Report Scope

In this report, the Global Diagnostic Specialty Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diagnostic Specialty Antibodies Market, By Antibody

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

Diagnostic Specialty Antibodies Market, By Application

• Dengue Diagnostics
• HIV Diagnostics
• Hepatitis Diagnosis
• Infectious Disease Diagnostics
• Oncology Diagnostics
• Tuberculosis Diagnostics

Diagnostic Specialty Antibodies Market, By End User

• Diagnostic Laboratories
• Hospitals
• Others

Diagnostic Specialty Antibodies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diagnostic Specialty Antibodies Market.

Available Customizations:

Global Diagnostic Specialty Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diagnostic Specialty Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Antibody (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies)
  • 5.2.2. By Application (Dengue Diagnostics, HIV Diagnostics, Hepatitis Diagnosis, Infectious Disease Diagnostics, Oncology Diagnostics, Tuberculosis Diagnostics)
  • 5.2.3. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Diagnostic Specialty Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Antibody
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diagnostic Specialty Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Antibody
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Diagnostic Specialty Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Antibody
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Diagnostic Specialty Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Antibody
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Diagnostic Specialty Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Antibody
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Diagnostic Specialty Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Antibody
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Diagnostic Specialty Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Antibody
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Diagnostic Specialty Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Antibody
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Diagnostic Specialty Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Antibody
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Diagnostic Specialty Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Antibody
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Diagnostic Specialty Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Antibody
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Diagnostic Specialty Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Antibody
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Diagnostic Specialty Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Antibody
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Diagnostic Specialty Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Antibody
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Diagnostic Specialty Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Antibody
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Diagnostic Specialty Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Antibody
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Diagnostic Specialty Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Antibody
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Diagnostic Specialty Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Antibody
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Diagnostic Specialty Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Antibody
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Diagnostic Specialty Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Antibody
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Diagnostic Specialty Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Antibody
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Diagnostic Specialty Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Antibody
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Diagnostic Specialty Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Antibody
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Diagnostic Specialty Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Antibody
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Diagnostic Specialty Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abcam Limited
• 15.3. Abbott Laboratories Inc
• 15.4. Bio-Rad Laboratories Inc
• 15.5. Agilent Technologies Inc
• 15.6. Creative Diagnostics
• 15.7. Thermo Fisher Scientific Inc
• 15.8. Becton Dickinson & Company
• 15.9. Merck KGaA
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer